Idelalisib

BreastfeedingPediatric
  • TRADE NAME: Zydelig (Gilead)
  • INDICATIONS: Relapsed chronic lymphocytic leukemia (with rituximab), follicular B-cell non-Hodgkin lymphoma, small lymphocytic lymphoma
  • CLASS: Phosphoinositide 3-kinase (PI3K) inhibitor
  • HALF-LIFE: 8 hours

FDA APPROVAL DATE: 07/23/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Carbamazepine, Copanlisib, Midostaurin, Neratinib, Phenytoin, Rifampin, St John's Wort, Strong CYP3A inducers and substrates

PREGNANCY CATEGORY: D

BLACK BOX WARNING
FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION

See full prescribing information for complete boxed warning.

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top